At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 52 enrolled
Drug / intervention
FGFR Inhibitor AZD4547drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
MATCH Treatment Subprotocol W: Phase II Study of AZD4547 in Patients With Tumors With Aberrations in the FGFR Pathway
In Brief
A Phase 2 clinical trial evaluating FGFR Inhibitor AZD4547 for Advanced Lymphoma and 5 related conditions. Completed, enrolled 52 participants across 1 site.
Detailed Summary
This phase II MATCH treatment trial identifies the effects of AZD4547 in patients whose cancer has genetic changes called FGFR gene alterations. AZD4547 may stop the growth of cancer cells by blocking FGFR proteins which may be needed for cell growth. Researchers hope to learn if AZD4547 will shrink this type of cancer or stop its growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Plasma Cell Myeloma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartMay 2016
Primary CompletionJun 2019
First PostedJun 2020
Study CompletionJun 2020
TodayJul 2026
First PostedJun 19, 2020
Enrollment StartMay 31, 2016
Primary CompletionJun 6, 2019
Study CompletionJun 30, 2020
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 6.0 years ago
Interventions
FGFR Inhibitor AZD4547drug
Given PO